An Innovative, Game-changing Approach to Cancer Therapeutics: Succeeding Where Others Have Failed
Download presentation
Please view our AGM notice here:
AGM Notice 2023-2024
ORIL’s key focus on the cancer market reflects the large and unmet medical need of the international cancer market.
Whilst major inroads in the discovery of the underlying causes of cancer have resulted in major breakthrough programs, long-term survival and quality of life during treatment remain major issues for patients diagnosed with this insidious disease.
The plant derived ORIL compounds in development have a combination of important features that differentiate the product from competitor cancer products either on-market or in development:
- Proof of concept in targeting and killing a multitude of cancer indications
- Unique first-in-class “shock” mode of action against cancer cells
- Enhancement of activity of co-administered anticancer agents
- Anti-angiogenic activity
- Anti-fungal activity
ORIL is not aware of any comparative product on the market that has all of the above features. ORIL’s technology and products with their associated features therefore have a distinct advantage over conventional anticancer agents that have limited specificity, adverse side effects but importantly fail to be effective after a relatively short period of time.
Key Investment Highlights
- ORIL has developed a unique anticancer drug with outstanding market potential.
- Platform technology based on a first-in-class mode of action that targets the cancer cell membrane.
- Focus on multiple dosage forms for multiple cancers using plant-based medicines.
- Multi-pronged formulation strategy to maximise application of core technology and minimise development risks.
- Lead compound optimised with preclinical studies progressing towards a first-in-human Phase I study.
- Lead compound supply ensured with patented process of synthesis.
- Strong IP Position with 4 patents granted, pending or in national phase entry in lead markets, and with others under development.
- Product pipeline in other therapeutic areas, based on platform technology.
- Internationally focused product registration strategy for the lead oncology product with defined path to market linked to clear milestones.
- Internationally recognised Board, management and advisory teams with a balance of skills, experience and substantial track records in science and business in the biotech and pharma industry.
